Furthermore, studies show that adjuvant treatment with EGFR-TKIs in resected EGFR-positive NSCLC results in longer disease-free survival (DFS) compared to patients receiving postoperative chemotherapy or placebo [36,37]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.